Nesfatin-1
Nesfatin-1 (NUCB2 Fragment)
Nesfatin-1 is an 82-amino acid anorexigenic peptide derived from the precursor protein NUCB2 (nucleobindin-2), primarily expressed in the hypothalamus, brainstem, and peripheral tissues including the stomach and pancreas. It is primarily investigated for its potent appetite-suppressing and metabolic-regulating properties, with research demonstrating significant reductions in food intake and body weight in animal models. Nesfatin-1 also shows emerging interest for its roles in glucose homeostasis, stress response modulation, and cardiovascular regulation.
Mechanism of Action
Nesfatin-1 acts independently of the leptin receptor and melanocortin-4 receptor (MC4R) pathway, though it does activate downstream oxytocin-expressing neurons in the paraventricular nucleus (PVN) of the hypothalamus to suppress feeding behavior. It crosses the blood-brain barrier in a non-saturable, non-energy-dependent manner and activates specific as-yet-unidentified G-protein-coupled receptors to reduce neuropeptide Y (NPY) and Agouti-related peptide (AgRP) signaling while enhancing pro-opiomelanocortin (POMC) tone. Peripherally, it enhances glucose-stimulated insulin secretion from pancreatic beta cells and modulates the HPA axis stress response via CRH neuron interactions.
Evidence by Health Goal(17 goals)
Dosing Protocols
30-60 minutes before the largest meal of the day
Cycle: 4-8 weeks on, 2-4 weeks off
Subcutaneous injection is the most studied peripheral route in research models. Human dosing remains largely extrapolated from rodent studies and limited human data; intracerebroventricular doses used in animal research are not applicable to humans. Research-grade purity (>98%) is critical. Start at the lower end of the dose range to assess tolerance.
Before meals or upon waking
Cycle: 4-6 weeks on, 2 weeks off
Intranasal delivery is being explored as a non-invasive method to achieve central (CNS) delivery, potentially bypassing systemic degradation. Bioavailability via this route is highly variable and poorly characterized in humans. This route is largely experimental with very limited human data.
Safety & Side Effects
Nesfatin-1 has not been approved by the FDA or EMA for any therapeutic indication, and its safety profile in humans is not well established beyond limited clinical observations and extensive preclinical data. While animal studies suggest a favorable short-term tolerability profile, long-term effects, immunogenicity risk, and endocrine consequences of exogenous administration in humans remain insufficiently characterized, warranting significant caution.
Possible Side Effects
- !Reduced appetite and caloric intake beyond desired levels, potentially leading to unintended weight loss
- !Nausea and mild gastrointestinal discomfort, particularly at higher doses
- !Hypoglycemia risk, especially when combined with insulin or insulin secretagogues due to enhanced insulin secretion
- !Anxiety or heightened stress response at higher doses due to HPA axis and CRH pathway activation
- !Injection site reactions including erythema, swelling, or localized discomfort with subcutaneous administration
- !Fatigue or lethargy secondary to significant caloric restriction or hypoglycemic episodes
- !Potential disruption of sleep architecture, as nesfatin-1 neurons interact with arousal and sleep-regulating circuits
Interactions
- -May potentiate hypoglycemic effects of insulin and sulfonylureas due to enhanced glucose-stimulated insulin secretion — monitor blood glucose closely
- -Additive appetite-suppressing effects possible when combined with GLP-1 receptor agonists (e.g., semaglutide, liraglutide), increasing risk of excessive caloric restriction
- -May amplify HPA axis activation when combined with corticotropin-releasing hormone (CRH) analogs or high-dose stimulants, potentially exacerbating anxiety or cortisol dysregulation
- -Potential additive blood pressure effects with antihypertensive medications given nesfatin-1's cardiovascular modulatory actions — use caution and monitor hemodynamics
- -May interact with leptin-sensitizing compounds or exogenous leptin therapy, as nesfatin-1 and leptin share downstream hypothalamic targets despite independent receptor systems
Cost & Where to Buy
Nesfatin-1 is available only as a research peptide and is not commercially approved. Cost varies significantly based on dose, vendor quality, purity certification, and quantity purchased. High-purity (>98% HPLC-verified) research-grade material commands a premium. Monthly cost estimates assume subcutaneous dosing at approximately 250-500 mcg/day with lyophilized peptide requiring reconstitution.
Search on Amazon